Moving Beyond Symptom-Based Psychiatry: Using Digital Cognitive Biomarkers to Stratify Patients, Confirm Pharmacology & Advance Precision Medicine in Schizophrenia
2:00 pm - Tuesday 1st December 2026
- Discover how objective digital cognitive biomarkers can identify biologically distinct patient subgroups, reducing the heterogeneity that has historically contributed to schizophrenia trial failures and enabling precision medicine approaches in psychiatry
- Explore how multimodal biomarkers can be integrated across the clinical development pathway, from patient selection and experimental medicine through to objective efficacy endpoints, to generate stronger proof-of-mechanism and improve decision-making
- Learn from Monument Therapeutics’ translational development strategy for MT1988, including early regulatory engagement around digital biomarker validation and the challenges of moving novel digital endpoints towards broader clinical adoption
